Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
SAN FRANCISCO, July 19, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has appointed Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer (CMO). In his role as CMO, Dr. Nuyten will have oversight for the company's clinical strategy and activities, including direct supervision of clinical sciences, clinical operations, data science and systems, medical affairs and clinical pharmacology. Dr. Nuyten will also serve as a member of the Company's Executive Committee.
Dr. Nuyten has extensive experience establishing and executing clinical strategy for oncology and immuno-oncology programs across all stages of development, from early-stage proof-of-concept to successful registrational studies. Prior to joining Nektar, he held several oncology development leadership roles at Bristol Myers Squibb and Pfizer.
"I am delighted to welcome Dr. Dimitry Nuyten to Nektar to lead our clinical development organization," said Howard Robin, President & CEO of Nektar Therapeutics. "Dimitry has an extensive track record in oncology drug development and is a proven leader in the field of immuno-oncology. His insight and expertise will be invaluable to Nektar as we advance development of our portfolio of immunotherapies in both solid tumor settings and hematological malignancies."
Dr. Nuyten most recently served as CMO at Aduro Biotech and as Consultant to Chinook Therapeutics, playing a key role in the merger between the two companies. He joined Aduro from Pfizer, where he was most recently Vice President and Immuno-Oncology Clinical Development Leader. At Pfizer, he oversaw clinical development for BAVENCIO® (avelumab), a human anti-programmed death ligand-1 (PD-L1) antibody approved for use in multiple indications. Dr. Nuyten designed and led the JAVELIN Bladder 100 Study which resulted in U.S. and European approvals for BAVENCIO® in the first-line maintenance setting for patients with bladder cancer. He also led development of additional programs in the immuno-oncology franchise, including pivotal and exploratory trials with immuno-oncology combination regimens. Prior to Pfizer, Dr. Nuyten served as Group Medical Director and Exploratory Development Team Leader and held other roles at Bristol Myers Squibb. While there, he led the development of several oncology programs, from pre-clinical stage through to proof-of-concept and oversaw a large portfolio of clinical trials.
"I am honored to join Nektar, a leader in the development of cytokine therapeutics, during this exciting time of important growth for the company," said Dr. Nuyten. "Nektar offers a unique opportunity to be part of an experienced leadership team advancing a deep pipeline of innovative new medicines with the potential to make a truly meaningful impact for patients."
Dr. Nuyten has authored numerous peer-reviewed publications, is co-inventor on multiple oncology patents and has received multiple awards, including from the American Society of Clinical Oncology (ASCO). Dr. Nuyten earned his M.D. from the University of Groningen and his Ph.D. in Cancer Biology from the University of Amsterdam Medical School, both in the Netherlands. He completed a residency in radiation oncology and a research fellowship in oncology at the Netherlands Cancer Institute in Amsterdam.
Brian Kotzin, M.D. who has served as the Company's interim CMO since January 2021, will continue in his prior role as Senior Vice President, Clinical Development and Head of Immunology.
"I'd like to thank Brian for his substantial contributions over the past six months as our interim Chief Medical Officer and am pleased that he will continue to lead the immunology area at Nektar," added Robin.
BAVENCIO® is a registered trademark of Merck KGaA.
Cautionary Note Regarding Forward-Looking Statements
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-appoints-dimitry-sa-nuyten-md-phd-as-senior-vice-president-and-chief-medical-officer-301336204.html
SOURCE Nektar Therapeutics
Company Codes: NASDAQ-NMS:NKTR